Bio-Rad Laboratories (NYSE:BIO) and PositiveID (OTCMKTS:PSID) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, profitability, earnings, analyst recommendations, institutional ownership, dividends and valuation.
Institutional & Insider Ownership
62.3% of Bio-Rad Laboratories shares are held by institutional investors. 28.0% of Bio-Rad Laboratories shares are held by insiders. Comparatively, 48.4% of PositiveID shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
This table compares Bio-Rad Laboratories and PositiveID’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk & Volatility
Bio-Rad Laboratories has a beta of 1.19, suggesting that its share price is 19% more volatile than the S&P 500. Comparatively, PositiveID has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500.
This is a summary of current recommendations and price targets for Bio-Rad Laboratories and PositiveID, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Bio-Rad Laboratories presently has a consensus price target of $339.17, indicating a potential upside of 41.53%. Given Bio-Rad Laboratories’ higher probable upside, equities analysts clearly believe Bio-Rad Laboratories is more favorable than PositiveID.
Earnings & Valuation
This table compares Bio-Rad Laboratories and PositiveID’s top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Bio-Rad Laboratories||$2.16 billion||3.32||$122.24 million||$4.10||58.45|
|PositiveID||$5.36 million||0.00||-$8.56 million||N/A||N/A|
Bio-Rad Laboratories has higher revenue and earnings than PositiveID.
Bio-Rad Laboratories beats PositiveID on 10 of the 11 factors compared between the two stocks.
Bio-Rad Laboratories Company Profile
Bio-Rad Laboratories, Inc. develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
PositiveID Company Profile
PositiveID Corporation, a life sciences and technology company, develops and sells molecular diagnostic systems for bio-threat detection and medical testing in the United States and internationally. It operates through three segments: Molecular Diagnostics, Medical Devices, and Mobile Labs. The company develops microfluidic systems for the automated preparation and performance of biological assays to detect biological threats and analyze biological samples at the point of need. It has a portfolio of intellectual property related to sample preparation and rapid medical testing applications. The company's microfluidic bio-agent autonomous networked detector (M-BAND) technology is a bio-aerosol monitor with integrated systems for sample collection, processing, and detection modules. Its M-BAND technology analyzes air samples for the detection of pathogenic bacteria, viruses, and toxins for up to 30 days. The company's FireflyDX is an automated pathogen detection system for rapid diagnostics for clinical and point-of-need applications. Its FireflyDX system detects and identifies common pathogens and diseases, such as E. coli, methicillin-resistant staphylococcus aureus, methicillin-susceptible staphylococcus aureus, clostridium difficile, Zika virus, Ebola virus, influenza, and others. In addition, PositiveID Corporation markets Caregiver, a non-contact clinical thermometer that measures forehead temperature in adults, children, and infants for hospitals, physicians' offices, medical clinics, nursing homes and other long-term care institutions, and acute care hospitals; and manufactures and sells specialty technology vehicles for mobile laboratory, command and communications applications, and mobile cellular systems. The company was formerly known as VeriChip Corporation and changed its name to PositiveID Corporation in November 2009. PositiveID Corporation was founded in 2001 and is headquartered in Delray Beach, Florida.
Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.